High-profile investigator tapped to lead $10M prostate cancer program

Charles Sawyers, a high-profile cancer drug specialist at Memorial Sloan-Kettering Cancer Center, has been tapped to help lead a $10 million effort to test personalized treatments for prostate cancer. He and a "dream team" of clinical investigators will test various combination therapies, including abiraterone. Sawyers played a leading role in the discovery of MDV3100 and ARN-509, two closely watched prostate cancer treatments now in development. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.